FBLG
FibroBiologics, Inc. (NASDAQ)
Healthcare — Biotechnology
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Price History
Fundamentals
| Market Cap | $4.72M |
| P/E Ratio (TTM) | - |
| Forward P/E | -0.20 |
| EPS (TTM) | $-7.02 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -754.75% |
| Debt/Equity | 95.31 |
| Recommendation | None |
| Analyst Target | $13.50 |
| Analysts | 2 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 46.4 |
| Beta | 1.15 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $14.68 |
| 52-Week Low | $0.73 |
| 50-Day Avg | $1.09 |
| 200-Day Avg | $5.09 |
| Avg Volume | 262.7K |
| Volume | 105.9K |
Performance Analysis
NEUTRALFBLG presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:09 UTC
Back to Screener Export Report